Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis

References

• Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, Broussard E, Stollman N, Giovanelli A, Smith B, et al. 2016. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 50:403–7.
   PubMed Web of Science ®Google Scholar
• Alhifany AA, Almutairi AR, Almangour TA, Shahbar AN, Abraham I, Alessa M, Alnezary FS, Cheema E. 2019. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open. 9:e031145.
   PubMed Web of Science ®Google Scholar
• Amiot A, Peyrin-Biroulet L. 2015. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 8:66–82.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. 2015. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 12:205–17.
   PubMed Web of Science ®Google Scholar
• Archer TP, Moran GW, Ghosh S. 2016. Tofacitinib in ulcerative colitis. Immunotherapy. 8:495–502.
   PubMed Web of Science ®Google Scholar
• Aroniadis OC, Brandt LJ, Greenberg A, Borody T, Kelly CR, Mellow M, Surawicz C, Cagle L, Neshatian L, Stollman N, et al. 2016. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated clostridium difficile infection: a multicenter experience. J Clin Gastroenterol. 50:398–402.
   PubMed Web of Science ®Google Scholar
• Basso PJ, Câmara NOS, Sales-Campos H. 2019. Microbial-Based therapies in the treatment of inflammatory bowel disease - an overview of human studies. Front Pharmacol. 9:1571.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, et al. 2017. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 66:569–80.
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. 2017. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 45:1291–302.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, et al. 2017. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 66:839–51.
   PubMed Web of Science ®Google Scholar
• Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, et al. 2019. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis. JAMA. 321:156–64.
   PubMed Web of Science ®Google Scholar
• Côté-Daigneault J, Bouin M, Lahaie R, Colombel J-F, Poitras P. 2015. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 3:419–28.
   PubMed Web of Science ®Google Scholar
• Cui G, Yuan A. 2018. A systematic review of epidemiology and risk factors associated with Chinese inflammatory bowel disease. Front Med (Lausanne). 5:183.
   PubMed Web of Science ®Google Scholar
• Ding X, Li Q, Li P, Zhang T, Cui B, Ji G, Lu X, Zhang F. 2019. Long-Term safety and efficacy of fecal microbiota transplant in active ulcerative colitis. Drug Saf. 42:869–80.
   PubMed Web of Science ®Google Scholar
• Ebrahimi Daryani N, Saghazadeh A, Moossavi S, Sadr M, Shahkarami S, Soltani S, Farhadi E, Rezaei N. 2017. Interleukin-4 and interleukin-10 gene polymorphisms in patients with inflammatory bowel disease. Immunol Invest. 46:714–29.
   PubMed Web of Science ®Google Scholar
• Fang H, Fu L, Wang J. 2018. Protocol for fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis. Biomed Res Int. 2018:8941340.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, et al. 2013. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 369:699–710.
   PubMed Web of Science ®Google Scholar
• Guo XL, Yan M. 2017. Pregnane X receptor polymorphisms and risk of inflammatory bowel disease: a meta-analysis. Immunol Invest. 46:566–76.
   PubMed Web of Science ®Google Scholar
• Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S. 2016. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 34:318–28.
   PubMed Web of Science ®Google Scholar
• Jharap B, Seinen ML, De Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJJ, van Bodegraven AA. 2010. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 16:1541–49.
   PubMed Web of Science ®Google Scholar
• Jiang XL, Cui HF, Gao J, Fan H. 2015. Low-dose infliximab for induction and maintenance treatment in chinese patients with moderate to severe active ulcerative colitis. J Clin Gastroenterol. 49:582–88.
   PubMed Web of Science ®Google Scholar
• Kamat N, Kedia S, Ghoshal UC, Nehra A, Makharia G, Sood A, Midha V, Gupta V, Choudhuri G, Ahuja V. 2019. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: a multicenter study. Indian J Gastroenterol. 38:44–54.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. 2015. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 12:720–27.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Ng SC. 2016. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 1:307–16.
   PubMed Web of Science ®Google Scholar
• Knox NC, Forbes JD, Van Domselaar G, Bernstein CN. 2019. The gut microbiome as a target for IBD treatment: are we there yet? Curr Treat Options Gastroenterol. 17:115–26.
   PubMedGoogle Scholar
• Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T. 2016. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 51:241–51.
   PubMed Web of Science ®Google Scholar
• Lai CY, Sung J, Cheng F, Tang W, Wong SH, Chan PKS, Kamm MA, Sung JJY, Kaplan G, Chan FKL, et al. 2019. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 49:354–63.
   PubMed Web of Science ®Google Scholar
• Laszlo M, Ciobanu L, Andreica V, Pascu O. 2016. Fecal transplantation indications in ulcerative colitis. Preliminary study. Clujul Med. 89:224–28.
   PubMedGoogle Scholar
• Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, et al. 2016. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent clostridium difficile infection: a randomized clinical trial. JAMA. 315:142–49.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jung ES, Lee JH, Hong SP, Kim TI, Kim WH, Cheon JH. 2012. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology. 59:1415–20.
   PubMed Web of Science ®Google Scholar
• Lin L, Liu X, Wang D, Zheng C. 2015. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore). 94:e556.
   PubMed Web of Science ®Google Scholar
• Martin D, Muñoz R, Yoder K, Allegretti JR, Smith M, Kassam Z. 2016. Assessing the landscape of fecal microbiota transplantation programs for recurrent clostridium difficile infection: a survey of existing practices among healthcare centers using an international public stool bank. Gastroenterology. 150:S238.
   Web of Science ®Google Scholar
• Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z,Reinisch W, et al. 2015. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 149:102–09.e6.
   Google Scholar
• Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al. 2018. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 390:2769–78.
   PubMed Web of Science ®Google Scholar
• O’Brien K, Osman M, Eysenbach L, Stoltzner Z, Day R, Nørgaard KS, Li W, Noh A, Mendolia G, Allegretti JR, et al. 2016. Clinical efficacy of fecal microbiota transplantation for recurrent clostridium difficile infection from an international public stool bank: results from a 1,406 patient multi-center cohort. Gastroenterology. 150:S539–S540.
   Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, et al. 2017. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 389:1218–28.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, et al. 2011. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 60:780–87.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JHA, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EMH, de Vos WM, et al. 2015. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 149:110–18. e4.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, et al. 2015. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 42:504–14.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 353:2462–76.
   Google Scholar
• Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, et al. 2014. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 146:85–95.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. 2012b. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 367:616–24.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, et al. 2017. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 376:1723–36.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, Colombel J, D’Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. 2012a. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 142:257–65.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, et al. 2019. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 381:1215–26.
   PubMed Web of Science ®Google Scholar
• Shohan M, Sabzevary-Ghahfarokhi M, Bagheri N, Shirzad H, Rahimian G, Soltani A, Ghatreh-Samani M, Deris F, Tahmasbi K, Shahverdi E, et al. 2018. Intensified Th9 response is associated with the immunopathogenesis of active ulcerative colitis. Immunol Invest. 47:700–11.
   PubMed Web of Science ®Google Scholar
• Smith M, Kassam Z, Edelstein C, Burgess J, Alm E. 2014. OpenBiome remains open to serve the medical community. Nat Biotechnol. 32:867.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, et al. 2014. Efficacy and safety of adalimumab in japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 49:283–94.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. 2017. Ulcerative colitis. Lancet. 389:1756–70.
   PubMed Web of Science ®Google Scholar
• Van der Valk ME, Mangen MJJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJL, et al. 2014. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 63:72–79.
   PubMed Web of Science ®Google Scholar
• Vasudevan A, Gibson PR, Van Langenberg DR. 2019. Systematic review: cost-effective strategies of optimizing anti-tumor necrosis and immunomodulators in inflammatory bowel disease. Inflamm Bowel Dis. 25:1462–73.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J. 2016. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 10:387–94.
   PubMed Web of Science ®Google Scholar